UOC
RAPT

UBS O'Connor’s RAPT Therapeutics RAPT Stock Holding History

UBS O'Connor’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,000
Closed -$63.2K – 434
2024
Q4 		$63.2K Buy
+5,000
New +$63.5K ﹤0.01% 358
2024
Q2 		– Sell
-9,136
Closed -$422K – 625
2024
Q1 		$656K Buy
9,136
+1,400
+18% +$195K 0.02% 314
2023
Q4 		$1.54M Sell
7,736
-3,991
-34% -$494K 0.05% 216
2023
Q3 		$1.56M Sell
11,727
-375
-3% -$61.2K 0.03% 275
2023
Q2 		$1.81M Buy
12,102
+596
+5% +$92.8K 0.04% 316
2023
Q1 		$1.69M Buy
+11,506
New +$2.33M 0.04% 352
2022
Q4 		– Sell
-8,727
Closed -$1.68M – 251
2022
Q3 		$1.68M Sell
8,727
-1,117
-11% -$211K 0.02% 670
2022
Q2 		$1.44M Buy
+9,844
New +$1.31M 0.01% 719
2020
Q2 		– Sell
-1,250
Closed -$213K – 426
2020
Q1 		$213K Buy
+1,250
New +$285K ﹤0.01% 300

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

UBS O'Connor's RAPT Position: Q1 2025 in Review

UBS O'Connor sold out of RAPT Therapeutics (RAPT) in Q1 2025, closing a stake of 5,000 shares — an estimated $63.2K sold.

UBS O'Connor first reported a position in RAPT in Q1 2020 and held it in 9 quarters. The position peaked at $1.81M in Q2 2023. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

  • UBS O'Connor reported no remaining RAPT Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 5,000 RAPT Therapeutics shares in Q1 2025, an estimated $63.2K.
  • UBS O'Connor first reported a position in RAPT Therapeutics in Q1 2020 and held it in 9 quarters.
  • UBS O'Connor's RAPT Therapeutics position peaked at $1.81M in Q2 2023.
  • 92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.